Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of intraportal infusion for colon cancer: a fair assessment?
Marsoni S, Torri V, Taiana A, Liberati A, Labianca R, Pancera G, Gray R, Clarke M. Marsoni S, et al. Among authors: torri v. J Clin Oncol. 1991 May;9(5):888-9. doi: 10.1200/JCO.1991.9.5.888. J Clin Oncol. 1991. PMID: 1958247 No abstract available.
GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon.
Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, Apolone G, Cifani S, Tinazzi A. Zaniboni A, et al. Among authors: torri v. Cancer. 1998 Jun 1;82(11):2135-44. doi: 10.1002/(sici)1097-0142(19980601)82:11<2135::aid-cncr7>3.0.co;2-u. Cancer. 1998. PMID: 9610692 Clinical Trial.
Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).
Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V. Mari E, et al. Among authors: torri v. Ann Oncol. 2000 Jul;11(7):837-43. doi: 10.1023/a:1008377101672. Ann Oncol. 2000. PMID: 10997811 Free article.
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. Cantù MG, et al. Among authors: torri v. J Clin Oncol. 2002 Mar 1;20(5):1232-7. doi: 10.1200/JCO.2002.20.5.1232. J Clin Oncol. 2002. PMID: 11870165 Clinical Trial.
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Parmar MK, et al. Among authors: torri v. Lancet. 2003 Jun 21;361(9375):2099-106. doi: 10.1016/s0140-6736(03)13718-x. Lancet. 2003. PMID: 12826431 Clinical Trial.
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. Manenti L, et al. Among authors: torri v. Eur J Cancer. 2003 Sep;39(13):1948-56. doi: 10.1016/s0959-8049(03)00427-1. Eur J Cancer. 2003. PMID: 12932675 Clinical Trial.
354 results